Positron emission tomography imaging of brain tumors
A wide variety of metabolic features of brain tumors can be imaged using PET, including glucose metabolism, blood flow, oxygen consumption, amino acid metabolism, and lipid synthesis. Currently, FDG is the most widely available PET tracer for body imaging and brain imaging. Malignant brain tumors, l...
Saved in:
| Published in: | Neuroimaging clinics of North America Vol. 12; no. 4; p. 615 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.11.2002
|
| Subjects: | |
| ISSN: | 1052-5149 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | A wide variety of metabolic features of brain tumors can be imaged using PET, including glucose metabolism, blood flow, oxygen consumption, amino acid metabolism, and lipid synthesis. Currently, FDG is the most widely available PET tracer for body imaging and brain imaging. Malignant brain tumors, like many other soft tissue tumors, show increased glucose metabolism, which is reflected on FDG-PET imaging. FDG-PET imaging of brain tumors provides information on tumor grade and prognosis. Compared with other organ systems, FDG-PET imaging of the brain presents unique challenges because of the high background glucose metabolism of normal gray matter structures. Coregistration of the MRI (or CT) and FDG-PET images is essential for accurate evaluation of brain tumors and is performed routinely at the authors' institution. The heterogeneous nature of gliomas can result in significant sampling errors when patients are biopsied for primary tumor diagnosis or recurrent disease. FDG-PET can be used to define the most metabolically active targets for stereotactic biopsy. This in turn can improve diagnostic accuracy and reduce the number of biopsy samples required. FDG-PET is also useful for evaluating residual or recurrent tumor following therapy, and can be used to survey patients with low-grade brain tumors for evidence of degeneration into high-grade malignancy. In the case of suspected tumor recurrence or progression, PET can aid in defining appropriate targets for biopsy. One limitation of FDG-PET is the occasional inability to distinguish radiation necrosis from recurrent high-grade tumor. A second limitation is that FDG-PET is less sensitive than contrast-enhanced MRI for detecting intracranial metastases, and it is the authors' experience that brain studies should not be included as part of routine whole-body PET studies. Other tracers, such as 11C-methionine and FCH, also avidly accumulate in brain tumors and have the advantage of low background cortical activity. The relationship between degree of uptake of these agents and tumor grade is not established. These tracers may be useful in specific clinical situations, however, such as tumor localization for treatment planning or evaluation of low-grade tumors. |
|---|---|
| AbstractList | A wide variety of metabolic features of brain tumors can be imaged using PET, including glucose metabolism, blood flow, oxygen consumption, amino acid metabolism, and lipid synthesis. Currently, FDG is the most widely available PET tracer for body imaging and brain imaging. Malignant brain tumors, like many other soft tissue tumors, show increased glucose metabolism, which is reflected on FDG-PET imaging. FDG-PET imaging of brain tumors provides information on tumor grade and prognosis. Compared with other organ systems, FDG-PET imaging of the brain presents unique challenges because of the high background glucose metabolism of normal gray matter structures. Coregistration of the MRI (or CT) and FDG-PET images is essential for accurate evaluation of brain tumors and is performed routinely at the authors' institution. The heterogeneous nature of gliomas can result in significant sampling errors when patients are biopsied for primary tumor diagnosis or recurrent disease. FDG-PET can be used to define the most metabolically active targets for stereotactic biopsy. This in turn can improve diagnostic accuracy and reduce the number of biopsy samples required. FDG-PET is also useful for evaluating residual or recurrent tumor following therapy, and can be used to survey patients with low-grade brain tumors for evidence of degeneration into high-grade malignancy. In the case of suspected tumor recurrence or progression, PET can aid in defining appropriate targets for biopsy. One limitation of FDG-PET is the occasional inability to distinguish radiation necrosis from recurrent high-grade tumor. A second limitation is that FDG-PET is less sensitive than contrast-enhanced MRI for detecting intracranial metastases, and it is the authors' experience that brain studies should not be included as part of routine whole-body PET studies. Other tracers, such as 11C-methionine and FCH, also avidly accumulate in brain tumors and have the advantage of low background cortical activity. The relationship between degree of uptake of these agents and tumor grade is not established. These tracers may be useful in specific clinical situations, however, such as tumor localization for treatment planning or evaluation of low-grade tumors.A wide variety of metabolic features of brain tumors can be imaged using PET, including glucose metabolism, blood flow, oxygen consumption, amino acid metabolism, and lipid synthesis. Currently, FDG is the most widely available PET tracer for body imaging and brain imaging. Malignant brain tumors, like many other soft tissue tumors, show increased glucose metabolism, which is reflected on FDG-PET imaging. FDG-PET imaging of brain tumors provides information on tumor grade and prognosis. Compared with other organ systems, FDG-PET imaging of the brain presents unique challenges because of the high background glucose metabolism of normal gray matter structures. Coregistration of the MRI (or CT) and FDG-PET images is essential for accurate evaluation of brain tumors and is performed routinely at the authors' institution. The heterogeneous nature of gliomas can result in significant sampling errors when patients are biopsied for primary tumor diagnosis or recurrent disease. FDG-PET can be used to define the most metabolically active targets for stereotactic biopsy. This in turn can improve diagnostic accuracy and reduce the number of biopsy samples required. FDG-PET is also useful for evaluating residual or recurrent tumor following therapy, and can be used to survey patients with low-grade brain tumors for evidence of degeneration into high-grade malignancy. In the case of suspected tumor recurrence or progression, PET can aid in defining appropriate targets for biopsy. One limitation of FDG-PET is the occasional inability to distinguish radiation necrosis from recurrent high-grade tumor. A second limitation is that FDG-PET is less sensitive than contrast-enhanced MRI for detecting intracranial metastases, and it is the authors' experience that brain studies should not be included as part of routine whole-body PET studies. Other tracers, such as 11C-methionine and FCH, also avidly accumulate in brain tumors and have the advantage of low background cortical activity. The relationship between degree of uptake of these agents and tumor grade is not established. These tracers may be useful in specific clinical situations, however, such as tumor localization for treatment planning or evaluation of low-grade tumors. A wide variety of metabolic features of brain tumors can be imaged using PET, including glucose metabolism, blood flow, oxygen consumption, amino acid metabolism, and lipid synthesis. Currently, FDG is the most widely available PET tracer for body imaging and brain imaging. Malignant brain tumors, like many other soft tissue tumors, show increased glucose metabolism, which is reflected on FDG-PET imaging. FDG-PET imaging of brain tumors provides information on tumor grade and prognosis. Compared with other organ systems, FDG-PET imaging of the brain presents unique challenges because of the high background glucose metabolism of normal gray matter structures. Coregistration of the MRI (or CT) and FDG-PET images is essential for accurate evaluation of brain tumors and is performed routinely at the authors' institution. The heterogeneous nature of gliomas can result in significant sampling errors when patients are biopsied for primary tumor diagnosis or recurrent disease. FDG-PET can be used to define the most metabolically active targets for stereotactic biopsy. This in turn can improve diagnostic accuracy and reduce the number of biopsy samples required. FDG-PET is also useful for evaluating residual or recurrent tumor following therapy, and can be used to survey patients with low-grade brain tumors for evidence of degeneration into high-grade malignancy. In the case of suspected tumor recurrence or progression, PET can aid in defining appropriate targets for biopsy. One limitation of FDG-PET is the occasional inability to distinguish radiation necrosis from recurrent high-grade tumor. A second limitation is that FDG-PET is less sensitive than contrast-enhanced MRI for detecting intracranial metastases, and it is the authors' experience that brain studies should not be included as part of routine whole-body PET studies. Other tracers, such as 11C-methionine and FCH, also avidly accumulate in brain tumors and have the advantage of low background cortical activity. The relationship between degree of uptake of these agents and tumor grade is not established. These tracers may be useful in specific clinical situations, however, such as tumor localization for treatment planning or evaluation of low-grade tumors. |
| Author | van der Westhuizen, Gert J Coleman, R Edward Wong, Terence Z |
| Author_xml | – sequence: 1 givenname: Terence Z surname: Wong fullname: Wong, Terence Z email: wong0015@mc.duke.edu organization: Division of Nuclear Medicine, Department of Radiology, Duke University Medical Center, Box 3949, Durham, NC 27710, USA. wong0015@mc.duke.edu – sequence: 2 givenname: Gert J surname: van der Westhuizen fullname: van der Westhuizen, Gert J – sequence: 3 givenname: R Edward surname: Coleman fullname: Coleman, R Edward |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/12687915$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9jztPxDAQhF0c4h7wE0CpEBSB3Y0T2yU68ZJOggLqyEnsEJTEh50U9--xxEE1q5lPq5k1W4xuNIxdINwiYHEXEHJKc-TqGugGALIszRZs9W8v2TqEr-gLQDhlS6RCCoX5ivE3F7rJuzExQxdCF4_JDa71ev95SLpBt93YJs4mldddzObB-XDGTqzugzk_6oZ9PD68b5_T3evTy_Z-l9Zc4pQqIAApODSiUMpwayupAGVV2KLRmUFFDXGTizpCSldgORKYggRlZCugDbv6_bv37ns2YSpjx9r0vR6Nm0MpSArMlYzg5RGcq8E05d7H5v5Q_u2kH8qrVF4 |
| CitedBy_id | crossref_primary_10_1016_j_clineuro_2010_09_012 crossref_primary_10_1017_S0007114513001384 crossref_primary_10_1200_JCO_2014_55_9575 crossref_primary_10_1148_rg_2020190103 crossref_primary_10_1002_cmdc_201900352 crossref_primary_10_1227_01_NEU_0000163598_59870_6D crossref_primary_10_1371_journal_pone_0148123 crossref_primary_10_1093_neuonc_not002 crossref_primary_10_1227_01_NEU_0000171642_49553_B0 crossref_primary_10_1007_s11307_007_0115_2 crossref_primary_10_1111_j_1440_1673_2008_02019_x crossref_primary_10_1016_j_ijrobp_2021_03_032 crossref_primary_10_37549_AR1698 crossref_primary_10_1515_raon_2016_0022 crossref_primary_10_1016_j_biomaterials_2015_07_028 crossref_primary_10_1097_01_rlu_0000246820_14892_d2 crossref_primary_10_1148_radiol_2451060731 crossref_primary_10_3171_jns_2006_104_2_238 crossref_primary_10_1053_j_semnuclmed_2007_08_001 crossref_primary_10_1007_s11307_010_0384_z crossref_primary_10_3389_fonc_2017_00178 crossref_primary_10_1016_j_nic_2020_09_010 crossref_primary_10_1109_TNS_2011_2125988 crossref_primary_10_3892_ol_2014_2680 crossref_primary_10_1097_MNM_0b013e32834f9b14 crossref_primary_10_1016_j_hoc_2019_08_008 crossref_primary_10_1016_j_nec_2009_08_003 crossref_primary_10_1002_lpor_202500102 crossref_primary_10_1002_hon_2761 crossref_primary_10_1093_neuonc_now243 crossref_primary_10_1371_journal_pone_0241157 crossref_primary_10_1007_s00381_007_0307_8 crossref_primary_10_1007_s00401_005_0023_y crossref_primary_10_2119_molmed_2010_00218 crossref_primary_10_1007_s13244_010_0040_9 crossref_primary_10_1158_0008_5472_CAN_14_2268 crossref_primary_10_1016_j_jacr_2020_01_037 crossref_primary_10_1007_s11060_005_9029_5 crossref_primary_10_1016_j_nec_2010_09_002 crossref_primary_10_1016_j_rcl_2019_07_003 crossref_primary_10_1038_nrc_2016_87 crossref_primary_10_3390_jcm10112313 crossref_primary_10_1016_j_cpet_2009_02_001 crossref_primary_10_1016_j_cpet_2012_06_009 crossref_primary_10_1200_JCO_2006_10_5825 crossref_primary_10_1016_j_ejrad_2008_04_018 crossref_primary_10_1016_j_nucmedbio_2015_06_001 crossref_primary_10_1053_j_semnuclmed_2007_04_002 crossref_primary_10_1016_j_mric_2013_02_004 crossref_primary_10_1177_197140091202500109 crossref_primary_10_1007_s11060_015_2032_6 crossref_primary_10_1227_01_NEU_0000143027_41632_2B crossref_primary_10_1002_nbm_1555 crossref_primary_10_1016_j_neuchi_2019_08_002 crossref_primary_10_1097_RLI_0b013e3181dc3671 crossref_primary_10_1016_j_cpet_2009_04_005 crossref_primary_10_1007_s11604_013_0190_z crossref_primary_10_1016_j_radonc_2014_09_004 crossref_primary_10_1016_j_ejrad_2011_01_080 crossref_primary_10_1158_1078_0432_CCR_06_2478 crossref_primary_10_1016_j_prro_2018_01_006 crossref_primary_10_1016_j_nucmedbio_2007_11_004 crossref_primary_10_1007_s00259_004_1517_x crossref_primary_10_1016_j_mednuc_2015_01_007 crossref_primary_10_1007_s40747_021_00563_y crossref_primary_10_1016_j_clineuro_2010_06_005 crossref_primary_10_1007_s11307_019_01388_5 crossref_primary_10_1016_j_cpet_2012_09_006 crossref_primary_10_1002_mco2_70020 crossref_primary_10_1227_01_NEU_0000338949_94496_85 crossref_primary_10_3389_frai_2022_780405 crossref_primary_10_1016_j_meddos_2005_12_006 crossref_primary_10_1016_j_cpet_2014_09_005 crossref_primary_10_1097_RLU_0b013e31821a290d crossref_primary_10_1007_s00330_010_1819_2 crossref_primary_10_1093_neuonc_nov118 crossref_primary_10_1148_radiol_2502071444 crossref_primary_10_1016_j_ics_2003_12_068 crossref_primary_10_3390_cancers15020364 crossref_primary_10_1177_0284185115575342 crossref_primary_10_1097_MNM_0b013e32832e1c7d crossref_primary_10_1007_s11060_012_0840_5 crossref_primary_10_1007_s11307_008_0152_5 crossref_primary_10_1097_RLU_0b013e31823926fc crossref_primary_10_1002_jmri_22563 crossref_primary_10_1080_17455030_2024_2366837 crossref_primary_10_3171_jns_2004_101_3_0476 crossref_primary_10_2174_0929867329666220328125206 crossref_primary_10_1097_RCT_0000000000000729 crossref_primary_10_3389_fonc_2023_1131013 crossref_primary_10_1002_hbm_24314 crossref_primary_10_37549_AR1753 crossref_primary_10_1007_s10278_019_00289_x crossref_primary_10_1007_s11060_007_9501_5 crossref_primary_10_1016_j_jocn_2007_12_008 crossref_primary_10_1371_journal_pone_0078913 crossref_primary_10_1200_JCO_2005_04_7522 crossref_primary_10_1002_jmri_20415 crossref_primary_10_1016_j_compbiomed_2024_108412 crossref_primary_10_1007_s00259_018_3948_9 crossref_primary_10_1093_nop_npv010 crossref_primary_10_1097_RLU_0b013e3181abb67e crossref_primary_10_1109_MEMB_2004_1337947 crossref_primary_10_1007_s11307_006_0063_2 crossref_primary_10_1097_RLU_0b013e3182485323 crossref_primary_10_1111_jon_12460 crossref_primary_10_1007_s00259_008_0780_7 crossref_primary_10_1016_j_jocn_2004_01_008 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/s1052-5149(02)00033-3 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| ExternalDocumentID | 12687915 |
| Genre | Journal Article Review |
| GroupedDBID | --- -RU .1- .FO 0R~ 123 1CY 1P~ 4.4 457 AAEDT AAEDW AALRI AAWTL AAXUO ABFRF ABJNI ABMAC ABQZK ADBBV AEFWE AENEX AEVXI AFCTW AFETI AFRHN AFTJW AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASTAF AXIYT B08 CGR COIAO CS3 CUY CVF DAHGL DU5 EBS ECM EIF EJD F5P FDB HZ~ NPM O9- OI. OU~ RIG SEL SES UDS UNMZH Z5R 7X8 ACDOS |
| ID | FETCH-LOGICAL-c481t-902008740d7699e4ffb89018b6f6da3e192d24e57c8749ab0f4120e627232fb02 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 161 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000182491400010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1052-5149 |
| IngestDate | Wed Oct 01 14:35:22 EDT 2025 Sat Sep 28 08:47:30 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c481t-902008740d7699e4ffb89018b6f6da3e192d24e57c8749ab0f4120e627232fb02 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 12687915 |
| PQID | 72871598 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_72871598 pubmed_primary_12687915 |
| PublicationCentury | 2000 |
| PublicationDate | 2002-11-01 |
| PublicationDateYYYYMMDD | 2002-11-01 |
| PublicationDate_xml | – month: 11 year: 2002 text: 2002-11-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Neuroimaging clinics of North America |
| PublicationTitleAlternate | Neuroimaging Clin N Am |
| PublicationYear | 2002 |
| SSID | ssj0037010 |
| Score | 2.029876 |
| SecondaryResourceType | review_article |
| Snippet | A wide variety of metabolic features of brain tumors can be imaged using PET, including glucose metabolism, blood flow, oxygen consumption, amino acid... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 615 |
| SubjectTerms | Blood Volume Brain Neoplasms - blood supply Brain Neoplasms - diagnosis Brain Neoplasms - diagnostic imaging Brain Neoplasms - metabolism Cerebrovascular Circulation Fluorodeoxyglucose F18 Humans Image Processing, Computer-Assisted Magnetic Resonance Imaging Prognosis Radiopharmaceuticals Tomography, Emission-Computed |
| Title | Positron emission tomography imaging of brain tumors |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/12687915 https://www.proquest.com/docview/72871598 |
| Volume | 12 |
| WOSCitedRecordID | wos000182491400010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV05T8MwFLYKZWDhEFc5PTDAEOHETmxLSAghKhaqDiB1i-zEljo0KU3K7-e9HDAhBpYoihzJevazv3d-hFxn3CtA0aBISnD0VsEblxxsHmQvUtbnzDRkE3IyUbOZng7IfV8Lg2mV_ZnYHNR5maGP_E4itI-1elh-BMgZhbHVjkBjgww5ABnc03L2HUPgknW9CGIwt8AQ-KnfwcK57uMNi25ZQ2jGf8eYzV0z3v3fLPfITocx6WO7KfbJwBUHREwxPWtVFhQZ3tBHRuty0TWspvNFw1ZES08tkkbQer0oV9UheR8_vz29BB1lQpAJFdaBZpjPIAXLZaK1E95bBTe-solPcsMd4Lk8Ei6WGQzSxjIvwoi5JJKArLxl0RHZLMrCnRAqo8xaA0tphBC5dNqD8QH6ajKjWWLtiFz1Ikhh3hhnMIUr11XaC2FEjlsppsu2c0YaRomSOoxP__z3jGy3vCvo7DgnQw_K6C7IVvZZz6vVZbPS8JxMX78ARxuw7A |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Positron+emission+tomography+imaging+of+brain+tumors&rft.jtitle=Neuroimaging+clinics+of+North+America&rft.au=Wong%2C+Terence+Z&rft.au=van+der+Westhuizen%2C+Gert+J&rft.au=Coleman%2C+R+Edward&rft.date=2002-11-01&rft.issn=1052-5149&rft.volume=12&rft.issue=4&rft.spage=615&rft_id=info:doi/10.1016%2Fs1052-5149%2802%2900033-3&rft_id=info%3Apmid%2F12687915&rft_id=info%3Apmid%2F12687915&rft.externalDocID=12687915 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1052-5149&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1052-5149&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1052-5149&client=summon |